Patent details

300456 Product Name: Pazopanib, desgewenst in de vorm van een farmaceutisch aanvaardbaar zout of solvaat, in het bijzonder Pazopanib hydrochloride.

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300456
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1343782
Status:
Expired Art. 14 (a) of the EC Regulations
Application number:
300456
Procedural language:
Dutch
First Applicant Residence Country:

Paediatric Extension

SPC Extension Filing Date:
29/12/2021
SPC Extension Agent/Owner Name:
Novartis AG , ir. F.A. Geurts c.s.
SPC Extension Status:
Extension Granted
SPC Extension Grant Date:
30/12/2021
SPC Extension Request Refusal Date:
SPC Extension Revocation Date:

Marketing Authorization

Marketing Authorization Number:
EU/1/10/628/001-004
Marketing Authorization Type:
EEA
Marketing Authorization Date:
16/06/2010
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
15/07/2010
First Marketing Authorization date:
16/06/2010
Grant date:
28/07/2010
Activation date:
19/12/2021
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
15/07/2010
SPC/SPC Extension Expiration Date:
15/12/2025
Lapsed By Expiration Date:
16/12/2025
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:

Applicant/holder

From:
22/10/2025
 
 

 

Name:
NOVARTIS PHARMA AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)

Historical Applicant/holder

From:
01/07/2016
To:
01/07/2016

 

Name:
LEO OSPREY LIMITED
Address:
980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (GB)

From:
01/07/2016
To:
22/10/2025

 

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)

From:
15/07/2010
To:
01/07/2016

 

Name:
GlaxoSmithKline LLC
Address:
One Franklin Plaza, P.O. Box 7929, 19101, PHILADELPHIA, PENNSYLVANIA, United States of America (US)

Agent

1

Name:
dr. R.C. van Duijvenbode c.s.
From:
18/03/2022
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

2

Name:
ir. F.A. Geurts c.s.
From:
15/07/2010
Address:
Octrooibureau Vriesendorp & Gaade B.V. Koninginnegracht 19, 2514 AB, Den Haag, Netherlands (NL)
To:
18/03/2022

Licensee

Name:
Novartis Pharma B.V.
From:
22/10/2025
Address:
Haaksbergweg 16, 1101 BX, Amsterdam, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
51/25
Publication date:
17/12/2025
Description:
Lapse or annulment

2

Bulletin Heading:
MED
Journal edition number:
46/25
Publication date:
12/11/2025
Description:
Other communications

3

Bulletin Heading:
CO
Journal edition number:
46/25
Publication date:
12/11/2025
Description:
Changes in the Netherlands Patent Register

4

Bulletin Heading:
SPC
Journal edition number:
01/22
Publication date:
05/01/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

5

Bulletin Heading:
SPC
Journal edition number:
01/22
Publication date:
05/01/2022
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

6

Bulletin Heading:
SPC
Journal edition number:
51/21
Publication date:
22/12/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

7

Bulletin Heading:
CO
Journal edition number:
39/16
Publication date:
28/09/2016
Description:
Changes in the Netherlands Patent Register

8

Bulletin Heading:
CO
Journal edition number:
39/16
Publication date:
28/09/2016
Description:
Changes in the Netherlands Patent Register

9

Bulletin Heading:
SPC
Journal edition number:
2010/24
Publication date:
04/08/2010
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

10

Bulletin Heading:
SPC
Journal edition number:
2010/22
Publication date:
21/07/2010
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)

Deed

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC202501731A
Date Registered:
22/10/2025
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
Freshfields Bruckhaus Deringer LLP
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
NOVARTIS PHARMA AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Licence

Change Kind/ Decision Type:
New licence registration
Deed Number:
RC202501781A
Date Registered:
22/10/2025
License Effective Date:
22/10/2025
License Expiration Date:
Scope of License:
Not Exclusive
Deed Filer:
Freshfields Bruckhaus Deringer LLP
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Licensee(s)

Name:
Novartis Pharma B.V.
Address:
Haaksbergweg 16, 1101 BX, Amsterdam, Netherlands (NL)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC201601899D
Date Registered:
01/07/2016
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. F.A. Geurts c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
LEO OSPREY LIMITED
Address:
980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (GB)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Change of owner(s)

Change Kind/ Decision Type:
Assignment
Deed Number:
RC201601899E
Date Registered:
01/07/2016
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
ir. F.A. Geurts c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:

Added Owner(s)

Name:
Novartis AG
Address:
Lichtstrasse 35, 4056, Basel, Switzerland (CH)

Changed Pledgee

Name:
Address:

Removed Usufructuary

Name:
Address:

Added Usufructuary

Name:
Address:

Changed Usufructuary

Name:
Address:

Annual Fee

Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
03/12/2024
Last Annual Fee Paid Number:
24
Last Annual Fee Paid Amount:
2200 Euro
Payer:
Arnold & Siedsma BV
Filing date Document type Document Description Number of pages File Type
30/12/2021 Certificate Certificate 1 PDF /6/5/4/0/0/0400300456/docs/300456_6_spcxcertificate20211230123829398.pdf
30/12/2021 Outgoing Correspondence Decision extension duration 1 PDF /6/5/4/0/0/0400300456/docs/300456_10_453618l504c.pdf
29/12/2021 SPC Documents Marketing Authorization SPC 3 PDF /6/5/4/0/0/0400300456/docs/300456_4_supplprotectioncertificate20211229120231509.pdf
29/12/2021 Application Form First filed application form 4 PDF /6/5/4/0/0/0400300456/docs/300456_11_applicationform20211229120103281.pdf
29/12/2021 SPC Documents Annex SPC 1 PDF /6/5/4/0/0/0400300456/docs/300456_12_supplprotectioncertificate20211229120726732.pdf
29/12/2021 SPC Documents Summary of the characteristics of the product 35 PDF /6/5/4/0/0/0400300456/docs/300456_13_supplprotectioncertificate20211229120649033.pdf
29/12/2021 Outgoing Correspondence Confirmation receipt request for extension 1 PDF /6/5/4/0/0/0400300456/docs/300456_14_453299l505.pdf
29/12/2021 SPC Documents Annex SPC 1 PDF /6/5/4/0/0/0400300456/docs/300456_15_supplprotectioncertificate20211229120810621.pdf
29/12/2021 SPC Documents Accompanying letter SPC 3 PDF /6/5/4/0/0/0400300456/docs/300456_16_supplprotectioncertificate20211229120152352.pdf
19/04/2016 SPC Documents Certificate SPC 1 PDF /6/5/4/0/0/0400300456/docs/300456_1_supplprotectioncertificate20211229014404698.pdf
19/04/2016 Outgoing Correspondence Decision grant 1 PDF /6/5/4/0/0/0400300456/docs/300456_8_outgoingcorrespondence20211229014340471.pdf
31/03/2016 SPC Documents Annex SPC 1 PDF /6/5/4/0/0/0400300456/docs/300456_7_supplprotectioncertificate20211229013925929.pdf
31/03/2016 Incoming Correspondence Paper Incoming Correspondence Paper 2 PDF /6/5/4/0/0/0400300456/docs/300456_17_incomingcorrespondencepaper20160406031047647.pdf
28/07/2010 SPC Documents Certificate SPC 1 PDF /6/5/4/0/0/0400300456/docs/300456_0_supplprotectioncertificate20211229013503109.pdf
28/07/2010 Outgoing Correspondence Outgoing Letter 1 PDF /6/5/4/0/0/0400300456/docs/300456_2_outgoingcorrespondence20100728.pdf
19/07/2010 Outgoing Correspondence Outgoing Letter 1 PDF /6/5/4/0/0/0400300456/docs/300456_18_outgoingcorrespondence20100719.pdf
15/07/2010 SPC Documents Marketing Authorization SPC 4 PDF /6/5/4/0/0/0400300456/docs/300456_3_supplprotectioncertificate20211229012600621.pdf
15/07/2010 SPC Documents Annex SPC 1 PDF /6/5/4/0/0/0400300456/docs/300456_5_supplprotectioncertificate20211229013019710.pdf
15/07/2010 SPC Documents Summary of the characteristics of the product 33 PDF /6/5/4/0/0/0400300456/docs/300456_9_supplprotectioncertificate20211229012829670.pdf
15/07/2010 Application Form First filed application form 2 PDF /6/5/4/0/0/0400300456/docs/300456_19_applicationform20100715.pdf